Oksaliplatin Kabi (Oxaliplatin)

Oxaliplatin, the active ingredient in Oksaliplatin Kabi, is a platinum‑based chemotherapy presented as a sterile powder for intravenous infusion for adult use. It is employed in the treatment of colorectal cancer and other solid tumours, typically as part of combination regimens.

GNH USA supplies Oksaliplatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic that interferes with DNA synthesis in malignant cells.

- Colorectal cancer: used in combination regimens to improve overall survival. - Gastric cancer: employed as part of first‑line chemotherapy protocols. - Pancreatic cancer: added to multi‑drug regimens to enhance response rates.

Oxaliplatin may cause a range of adverse reactions that require monitoring.

Common Side Effects: - Nausea and vomiting. - Peripheral neuropathy (tingling or numbness). - Fatigue and weakness. - Neutropenia (low white blood cell count).

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions. - Severe thrombocytopenia (low platelet count). - Pulmonary toxicity (interstitial pneumonitis). - Acute hemolytic anemia.

Prior to initiating therapy, several safety considerations should be addressed. - Renal function: assess baseline creatinine and adjust if impaired. - Hepatic function: monitor liver enzymes before and during treatment. - Peripheral neuropathy: monitor for sensory changes and adjust dose if severe. - Myelosuppression: perform regular CBCs to detect neutropenia or thrombocytopenia. - Pregnancy: avoid use; drug is contraindicated in pregnant women. - Store at controlled room temperature (below 25°C): keep in original container, protect from light and moisture.

Oxaliplatin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use of other platinum agents: increased neurotoxicity. - High‑dose vitamin C: may reduce efficacy. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., cisplatin): monitor renal function. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Serotonergic agents used for severe nausea: monitor for serotonin syndrome.